Honokiol inhibits pathological retinal neovascularization in oxygen-induced retinopathy mouse model

Biochemical and Biophysical Research Communications

Volumn 438, Issue 4, 2013, Pages 697-702

  Vavilala, Divya Teja ^a   O'Bryhim, Bliss E ^b   Ponnaluri, V K Chaithanya ^a   White, R Sid ^b   Radel, Jeff ^b   Symons, R C Andrew ^b,c   Mukherji, Mridul ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Honokiol; Hypoxia signaling; OIR model; Retinopathy; Transcription regulation

Indexed keywords

DIGOXIN; DOXORUBICIN; FLUORESCENT DYE; HONOKIOL; OXYGEN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINA CELL; RETINA NEOVASCULARIZATION; RETINOPATHY; RNA EXTRACTION; SIGNAL TRANSDUCTION;

ANGIOGENESIS; HIF; HONOKIOL; HRE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA RESPONSE ELEMENT; HYPOXIA SIGNALING; INTRAPERITONEAL; IP; OIR; OIR-MODEL; OXYGEN-INDUCED RETINOPATHY; P; PHD; POSTNATAL DAY; PROLYL HYDROXYLATION DOMAIN; RETINOPATHY; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; VHL; VON HIPPEL-LINDAU;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIPHENYL COMPOUNDS; CELL LINE; DIGOXIN; DOXORUBICIN; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LIGNANS; MICE; MICE, INBRED C57BL; OXYGEN; RETINA; RETINAL NEOVASCULARIZATION; TRANSCRIPTIONAL ACTIVATION;

EID: 84883297432     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.07.118     Document Type: Article

References (27)

1. Campochiaro P.A. Ocular neovascularization. J. Mol. Med. (Berl.) 2013, 91:311-321.
2. Stewart M.W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 2012, 87:77-88.
3. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 1995, 92:10457-10461.
4. Ozaki H., Seo M.S., Ozaki K., Yamada H., Yamada E., Okamoto N., Hofmann F., Wood J.M., Campochiaro P.A. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 2000, 156:697-707.
5. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1432-1444.
6. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
7. Zhang S.X., Ma J.X. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog. Retin Eye Res. 2007, 26:1-37.
8. Semenza G.L. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr. Pharm. Des. 2009, 15:3839-3843.
9. Ban H.S., Uto Y., Nakamura H. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004-2010). Expert Opin. Ther. Patient 2011, 21:131-146.
10. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., Semenza G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 2008, 105:19579-19586.
11. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. USA 2009, 106:2353-2358.
12. Yoshida T., Zhang H., Iwase T., Shen J., Semenza G.L., Campochiaro P.A. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J. 2010, 24:1759-1767.
13. Iwase T., Fu J., Yoshida T., Muramatsu D., Oveson B., Han B., Wu M., Semenza G.L., Hanes J., Campochiaro P.A. Safe and effective polymeric-doxorubicin conjugate nanoparticles for prolonged antiangiogenic activity in the Eye. ARVO Annual Meeting E-Abstract 2012, 3008.
14. Vavilala D.T., Chaithanya Ponnaluri V.K., Vadlapatla R.K., Pal D., Mitra A.K., Mukherji M. Honokiol inhibits HIF pathway and hypoxia-induced expression of histone lysine demethylases. Biochem. Biophys. Res. Commun. 2012, 422:369-374.
15. Ponnaluri V.K., Vadlapatla R.K., Vavilala D.T., Pal D., Mitra A.K., Mukherji M. Hypoxia induced expression of histone lysine demethylases: implications in oxygen-dependent retinal neovascular diseases. Biochem. Biophys. Res. Commun. 2011, 415:373-377.
16. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.
17. Connor K.M., Krah N.M., Dennison R.J., Aderman C.M., Chen J., Guerin K.I., Sapieha P., Stahl A., Willett K.L., Smith L.E. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 2009, 4:1565-1573.
18. Stahl A., Connor K.M., Sapieha P., Willett K.L., Krah N.M., Dennison R.J., Chen J., Guerin K.I., Smith L.E. Computer-aided quantification of retinal neovascularization. Angiogenesis 2009, 12:297-301.
19. Vavilala D.T., Ponnaluri V.K., Vadlapatla R.K., Pal D., Mitra A.K., Mukherji M. Honokiol inhibits HIF pathway and hypoxia-induced expression of histone lysine demethylases. Biochem. Biophys. Res. Commun. 2012, 422:369-374.
20. Wong C.C., Zhang H., Gilkes D.M., Chen J., Wei H., Chaturvedi P., Hubbi M.E., Semenza G.L. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. (Berl.) 2012, 90:803-815.
21. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12:853-859.
22. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 2007, 26:341-352.
23. Slomiany M.G., Rosenzweig S.A. IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest. Ophthalmol. Vis. Sci. 2004, 45:2838-2847.
24. Geisen P., McColm J.R., King B.M., Hartnett M.E. Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Curr. Eye Res. 2006, 31:739-748.
25. Forooghian F., Razavi R., Timms L. Hypoxia-inducible factor expression in human RPE cells. Br. J. Ophthalmol. 2007, 91:1406-1410.
26. Praveen Kumar V., Gajendra Reddy R., Vo D.D., Chakravarty S., Chandrasekhar S., Gree R. Synthesis and neurite growth evaluation of new analogues of honokiol, a neolignan with potent neurotrophic activity. Bioorg. Med. Chem. Lett. 2012, 22:1439-1444.
27. DeNiro M., Al-Halafi A., Al-Mohanna F.H., Alsmadi O., Al-Mohanna F.A. Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. Mol. Pharmacol. 2010, 77:348-367.